Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.03.2023 | Case report

Evolocumab

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Skove S, et al. THERAPEUTIC LDL-C LOWERING WITH PCSK9 DIRECTED OLIGONUCLEOTIDE THERAPY (INCLISIRAN) IN A PATIENT WITH FAMILIAL HYPERLIPIDEMIA (FH) REFRACTORY TO PCSK-9 MONOCLONAL ANTIBODY (EVOLOCUMAB). Journal of the American College of Cardiology 81 (Suppl. A): 2474, No. 8, et al. Mar 2023. Available from: URL: http://doi.org/10.1016/S0735-1097%2823%2902918-2 [abstract] Skove S, et al. THERAPEUTIC LDL-C LOWERING WITH PCSK9 DIRECTED OLIGONUCLEOTIDE THERAPY (INCLISIRAN) IN A PATIENT WITH FAMILIAL HYPERLIPIDEMIA (FH) REFRACTORY TO PCSK-9 MONOCLONAL ANTIBODY (EVOLOCUMAB). Journal of the American College of Cardiology 81 (Suppl. A): 2474, No. 8, et al. Mar 2023. Available from: URL: http://​doi.​org/​10.​1016/​S0735-1097%2823%2902918-2 [abstract]
Metadaten
Titel
Evolocumab
Lack of efficacy: case report
Publikationsdatum
01.03.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-36190-x

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Ibrutinib

Case report

Flecainide